AARD (Aardvark Therapeutics) Total Assets: $98.59 Mil (As of Mar. 2026)


AARD Aardvark Therapeutics Inc AARD
12 GF Score
Price $5.18
! 1 Warning Sign
View Full Analysis

What is Aardvark Therapeutics Total Assets?

Aardvark Therapeutics AARD +8.14% 12 Total Assets is $98.59 Mil as of Mar. 2026. GuruFocus rates AARD with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Aardvark Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $98.59 Mil.

During the past 12 months, Aardvark Therapeutics's average Total Assets Growth Rate was 86.10% per year. During the past 3 years, the average Total Assets Growth Rate was 122.20% per year.

During the past 4 years, Aardvark Therapeutics's highest 3-Year average Total Assets Growth Rate was 122.20%. The lowest was 122.20%. And the median was 122.20%.

Total Assets is connected with ROA %. Aardvark Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -80.04%. Total Assets is also linked to Revenue through Asset Turnover. Aardvark Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Aardvark Therapeutics  (NAS:AARD) Total Assets Explanation

Total Assets is connected with ROA %.

Aardvark Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-86.352/( (117.181+98.59)/ 2 )
=-86.352/107.8855
=-80.04 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Aardvark Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (117.181+98.59)/ 2 )
=0/107.8855
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Aardvark Therapeutics Total Assets Related Terms

Aardvark Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Aardvark Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aardvark Therapeutics Total Assets Chart

Aardvark Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Assets
16.76 10.54 77.51 117.18

Aardvark Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 157.03 147.48 133.23 117.18 98.59
AARD
12GF Score
Aardvark Therapeutics Inc AARD
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aardvark Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Aardvark Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=106.633+10.548
=117.18

Aardvark Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=86.986+11.604
=98.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $98.59 Mil mean?
Aardvark Therapeutics (AARD) has a Total Assets of $98.59 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Aardvark Therapeutics and its competitors.
Is Aardvark Therapeutics' Total Assets too high?
Aardvark Therapeutics' current Total Assets is $98.59 Mil. Overall, Aardvark Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aardvark Therapeutics' Total Assets compare to KLRS and VANI?
Aardvark Therapeutics' Total Assets of $98.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Aardvark Therapeutics and its competitors. Aardvark Therapeutics's current Total Assets is $98.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aardvark Therapeutics stock overvalued right now?
Aardvark Therapeutics (AARD) has a current Total Assets of $98.59 Mil. The current Total Assets is $98.59 Mil. Aardvark Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Aardvark Therapeutics (AARD), the current Total Assets is $98.59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aardvark Therapeutics Business Description

Address 4370 La Jolla Village Drive, Suite 1050, San Diego, CA, USA, 92122
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
12GF Score

Get the complete analysis for AARD

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.18
Price